CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients

By Chao Niu, Hua Yan, Ting Yu, Hui-Ping Sun, Jian-Xiang Liu, Xu-Song Li, Wen Wu, Fen-Qin Zhang, Yu Chen, Li Zhou, Jun-Min Li, Xiao-Ying Zeng, Ren-Rong Ou Yang, Mi-Man Yuan, Mei-Yu Ren, Feng-Ying Gu, Qi Cao, Bo-Wei Gu, Xin-Ying Su, Guo-Qiang Chen, Shu-Min Xiong, Ting-dong Zhang, Samuel Waxman, Zhen-Yi Wang, Zhu Chen, Jiong Hu, Zhi-Xiang Shen, and Sai-Juan Chen

Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As$_2$O$_3$) treatment. Clinical complete remission (CR) was obtained in 8 of 11 (72.7%) newly diagnosed cases. However, As$_2$O$_3$ treatment resulted in hepatic toxicity in 7 cases including 2 deaths, in contrast to the mild liver dysfunction in one third of the relapsed patients. Forty of forty-seven (85.1%) relapsed patients achieved CR. Two of three nonresponders showed clonal evolution at relapse, with disappearance of t(15;17) and PML-RAR$_a$ fusion gene in 1 and shift to a dominant AML-1-ETO population in another, suggesting a correlation between PML-RAR$_a$ expression and therapeutic response. In a follow-up of 33 relapsed cases over 7 to 48 months, the estimated disease-free survival (DFS) rates for 1 and 2 years were 63.6% and 41.6%, respectively, and the actual median DFS was 17 months.

Most acute promyelocytic leukemia (APL) patients have the characteristic chromosome translocation t(15;17) that juxtaposes PML gene on chromosome 15 andRAR$_a$ gene on chromosome 17, forming a PML-RAR$_a$ fusion gene. The PML-RAR$_a$ protein encoded by the fusion gene plays an important role in the pathogenesis of APL. Although 70% to 85% of APL patients achieved complete remission (CR) by cytotoxic chemotherapy, a significant part of patients experienced severe complications, necessitating intensive supportive care, which is hardly available in most developing countries. The use of differentiation therapy with all-trans retinoic acid (ATRA) has not only opened a new approach in cancer treatment, but also rendered remission induction relatively easy in most of the APL patients. Moreover, the overall disease-free survival in the patients with CR achieved by ATRA and consolidated as well as maintained by chemotherapy has been significantly higher than those treated with chemotherapy alone for remission induction, consolidation, and maintenance treatment. In spite of these advances, 30% to 40% of patients would relapse within 5 years after CR. The majority of these patients lost sensitivity to ATRA and chemotherapy and died shortly thereafter.

In early 1970s, Zhang et al. from Harbin Medical University in Northeast China, found that intravenous administration of arsenic trioxide (As$_2$O$_3$) with relatively small doses (10 mg/d) was effective in treating patients with APL, lymphoma, and liver cancer. However, it was only recently that the therapeutic effect of As$_2$O$_3$ was proven in APL patients by several groups in China. Recently, Soignet et al. confirmed in Western population that As$_2$O$_3$ treatment achieved CR in 11 out of 12 relapsed APL patients.

In vitro studies indicate that As$_2$O$_3$ may exert biphasic action on APL cells, induction of apoptosis at higher concentrations (0.1 to 0.5µmol/L), and partial differentiation at lower concentrations (0.1 to 0.5µmol/L). As$_2$O$_3$, at both high and low concentrations, is able to trigger the degradation of PML-RAR$_a$ fusion protein. Interestingly, the drug was equally effective in inducing apoptosis in ATRA–sensitive and –resistant APL cells.

Several important issues, nevertheless, remain to be addressed for As$_2$O$_3$ treatment in APL. Is As$_2$O$_3$ treatment equally effective for newly diagnosed APL patients? Could the drug induce a molecular remission in these patients as well as in relapsed cases? What could be the possible prognostic param-

From Shanghai Institute of Hematology, Department of Hematology/Oncology, Rui Jin Hospital/Samuel Waxman Cancer Research Foundation Joint Center for Cancer Differentiation Therapy Sponsored by Reliance Group Holdings Inc, Rui-Jin Hospital, Ren-Ji Hospital; Xin-Hua Hospital, Shanghai Second Medical University, Shanghai, China; Zhong-Shan Hospital, Shanghai, China; Gan-Quan Hospital, Shanghai, China; and First Hospital Affiliated with Harbin Medical University, Harbin, China.

Submitted January 5, 1999; accepted July 7, 1999.

C.N. and H.Y. contributed equally to this work.

Supported in part by the Chinese Climbing Project, National Natural Sciences Foundation of China, Shanghai Municipal Commission for Sciences and Technologies, Samuel Waxman Cancer Research Foundation, and the Clyde Wu Foundation of Shanghai Institute of Hematology.

Address reprint requests to Sai-Juan Chen, MD, PhD, or Jiong Hu, MD, Shanghai Institute of Hematology, Department of Hematology/Oncology, Rui Jin Hospital, Shanghai Second Medical University, 197 Rui Jin Road II, 200025, Shanghai, China; email: zchen@ms.stn.sh.cn.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1999 by The American Society of Hematology.
eters and suitable postremission treatment in relapsed APL patients rescued with As$_2$O$_3$? In this report, we describe the results of a comprehensive study on 11 previously untreated and 47 relapsed APL cases.

PATIENTS AND METHODS

Patients. The diagnosis of APL was established on the basis of clinical presentation, morphological criteria of the French-American-British (FAB) classification, cytogenetic evaluation for t(15;17), and reverse transcription polymerase chain reaction (RT-PCR) analysis for PML-RAR$\alpha$ transcripts. Two groups of patients, newly diagnosed and relapsed APL, entered into this As$_2$O$_3$ treatment multicenter study including five hospitals in Shanghai (Rui-Jin Hospital, Ren-Ji Hospital, Xin-Hua Hospital, Zhong-Shan Hospital, and Gan-Quan Hospital). Between July 1996 and April 1998, 11 cases of newly diagnosed APL, without exposure to any antileukemia treatment were included into this study. Between December 1994 and February 1998, 47 relapsed patients (2 at the second relapse, 2 at the third relapse, and 43 cases at the first relapse) who had received ATRA for the remission induction and chemotherapy/ATRA in the following consolidation and maintenance therapy were enrolled. However, none of them were still taking ATRA at the time of relapse. Informed consent was obtained for every patient entering into this study. The main clinical and hematological characteristics of the evaluated patients are shown in Table 1. Of note, part of the data concerning As$_2$O$_3$ induction therapy in 15 cases in the relapsed group was presented in our previous report. 12

Induction therapy. As$_2$O$_3$ solution was prepared by the Pharmacy of Traditional Chinese Medicine in the First Hospital affiliated with Harbin Medical University of China. The following protocol was used: 10 mg As$_2$O$_3$ (10 mL, 0.1% aqua solution) was diluted in 500 mL of 5% glucose-normal saline solution for intravenous drip over 2 to 3 hours per day, for 6-weeks duration. If necessary, a second course was performed after an interval of 7 days. Those patients who failed to reach CR after 2 courses were considered as nonresponders (NR) and were treated with chemotherapy.

Supportive care. Sequential measurements of complete blood cell count (every other day), bone marrow (BM) cytology (every 10 days), renal functions, and hepatic functions (every 1 to 2 weeks) were performed during As$_2$O$_3$ remission induction treatment. Measurement of coagulation and fibrinolysis parameters, including fibrinogen, DD dimers, fibrin degradation product (FDP), prothrombin time, and activated partial thromboplastin time was performed by standard methods for each patient before and during the As$_2$O$_3$ treatment. Coagulopathy was treated at the physician’s discretion using low-dose heparin, platelet transfusion, and fresh plasma. Patients were administered hydroxyurea or moderate chemotherapy (Daunorubicin: 40 mg/m$^2$/d × 3 d; Ara-C: 100 mg/m$^2$/d × 3 to 5 d) when their white blood cell (WBC) counts were over 30 to 40 × 10$^9$/L, based on the observation that there seems to be less clinical syndrome associated with As$_2$O$_3$-induced hyperleukocytosis as compared with ATRA–induced ones. Symptomatic therapy was performed without discontinuation of As$_2$O$_3$ when moderate side effects occurred while As$_2$O$_3$ was withdrawn in the case of serious toxic effects.

Definition of outcomes. Achievement of CR required patients to have no clinical evidence of APL, untransfused hemoglobin greater than 10 g/dL, neutrophils greater than 1.5 × 10$^9$/L, platelets greater than 100 × 10$^9$/L, BM to be normocellular or moderately hypocellular with less than 5% promyelocytes, and absence of leukemic cells with cytoplasmic Auer rods. Disease-free survival (DFS) was defined as the time from CR to relapse, death from any cause, or censoring of the data on the patients.

Follow-up. After CR was achieved with As$_2$O$_3$, the patients were treated by three different therapeutic protocols for consolidation: (1) chemotherapy group: continuous treatment with chemotherapy DA/MA monthly [Daunorubicin(D): 45 mg/m$^2$/d on day 1 to 3 or Mitoxantrone(M) 8 mg/d on day 1 to 3, and Ara-C(A) 100 to 200 mg/d on day 1 to 7]. One course every 2 months in the first year, every 3 months in the second year, and every 4 months in the third year. (2) As$_2$O$_3$ group: 10 mg As$_2$O$_3$ daily continuing 28 to 30 days as a course with approximately 30 to 60 days interval between two cycles within the first year, approximately 7 to 14 days as a course every 2 months over the second and third year. (3) Chemotherapy and As$_2$O$_3$ combination group: chemotherapy was administered as group (1) while As$_2$O$_3$ was used as group (2), but during the interval of chemotherapy. No randomization was performed due to the short supply of As$_2$O$_3$ for some of the patients and the refusal of some patients to further use of chemotherapy or As$_2$O$_3$. Follow-up was terminated on March 31, 1999.

Statistical analysis. Association between pairs of patients’ covariates, including individual characteristics and the treatment indicator, was evaluated using Fisher’s exact test and generalized exact test. Analysis of DFS and overall survival were performed with Kaplan-Meier product-limit estimation.

Cytogenetic studies. Metaphase chromosomes were prepared from BM cells after short-term culture (24 hours). RHG-banding technique was used and karyotype analysis was performed according to International System for Human Cytogenomic Nomenclature (ISCN). 18

RT-PCR. RT-PCR analysis for PML-RAR$\alpha$ transcripts was performed according to our previously described methods. 19

Fluorescence in situ hybridization (FISH). Dual-color FISH was performed with the probe YAC 185B2, P1 164 (biotinylated), and YAC 417D9, Co664 (digoxigenin-labeled) prepared by nick translation for PML-RAR$\alpha$ and AML1-ETO detection, respectively. Chromosome painting was performed employing whole chromosome painting (WCP) probes for chromosome 5, 15, 17, and 22 (Cambo, Cambridge, UK, & Oncor, Gaithersburg, MD). The procedure was as recommended by the manufacturer. In brief, slides were denatured in 70% formamide/2 × SSC (1 × SSC: 0.15 mol/L NaCl and 0.015 mol/L natriumcitrate, pH 7.0) at 70°C. Then, the probes were applied to denatured slides and hybridized at 37°C overnight. After posthybridization washing, probes were detected using avidin conjugated Texas Red and fluorescein isothiocyanate (FITC)-labeled antibodies. DAPI was used as a counterstain.

Combination of Wright’s staining and dual-color FISH. BM samples collected before and 20 days after As$_2$O$_3$ treatment from five patients (case 21, 22, 29, 35, and 37) were subjected to simultaneous morphological and FISH analysis. The procedures described by Haferlach et al 20

Table 1. Characteristics of Patients With APL in the Present Study

<table>
<thead>
<tr>
<th></th>
<th>Newly Diagnosed APL</th>
<th>Relapsed APL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluated cases</td>
<td>11</td>
<td>47</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>3/8</td>
<td>29/18</td>
</tr>
<tr>
<td>Median age (range, years)</td>
<td>41 (24 to 60)</td>
<td>38 (7 to 55)</td>
</tr>
<tr>
<td>Median WBC (range, × 10$^9$/L)</td>
<td>2.2 (1.1 to 65.0)</td>
<td>3.4 (0.6 to 56.0)</td>
</tr>
<tr>
<td>&lt; 2</td>
<td>4</td>
<td>14</td>
</tr>
<tr>
<td>2 to 10</td>
<td>4</td>
<td>24</td>
</tr>
<tr>
<td>10 to 20</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>&gt; 20</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Median RBC (range, × 10$^{12}$/L)</td>
<td>2.33 (1.03 to 2.96)</td>
<td>3.65 (1.78 to 5.31)</td>
</tr>
<tr>
<td>Median hemoglobin (range, g/L)</td>
<td>70 (51 to 97)</td>
<td>109 (56 to 180)</td>
</tr>
<tr>
<td>Median platelet (range, × 10$^9$/L)</td>
<td>20 (10 to 50)</td>
<td>38 (4 to 236)</td>
</tr>
<tr>
<td>Median percentage of blasts and promyelocytes in BM (range)</td>
<td>87.5 (38.0 to 95.5)</td>
<td>66.0 (12.5 to 95.0)</td>
</tr>
</tbody>
</table>
were used with modification. Briefly, mononuclear cell fractions were isolated from BM aspirate by Ficoll-Hypaque density gradient centrifugation, and were spun onto slides by cytopsin (Shandon, Runcorn, UK; 800 rpm, 4 minutes). For morphological observation, Wright’s staining was performed. Leukemic promyelocytes or myelocyte-like cells were photographed by conventional microphotography (Olympus, Tokyo, Japan), and the location of the cells was documented. Slides were incubated in xylene for 5 minutes to remove the cedar wood oil, fixed in Carnoy’s fixation (methanol: acetic acid, 3:1) for 15 minutes, washed in phosphate-buffer solution for 1 minute, and fixed again in paraformaldehyde for 1 minute. The PML-RAR fusion gene was detected by using t(15;17) translocation DNA probe (Oncor, Gaithersburg, MD). Dual-color FISH was performed following the manufacturer’s instructions. The results were observed through a triple-bandpass filter (Olympus) equipped on an Olympus microscope and pictured with Kodak 400 film (Eastman Kodak, Rochester, NY).

RESULTS
Newly Diagnosed Patient Group

CR. There were 11 newly diagnosed APL patients entered into this study, 7 cases were treated with As2O3 and 4 with combined As2O3 and chemotherapy. Eight (72.7%) entered into CR, and the median time to obtain CR was 35 days (range, 30 to 36 days) with a median dosage of 295 mg (Table 2). One patient died of cerebral hemorrhage on day 1 of As2O3 treatment. The other 2 patients (cases 2 and 8) died on day 15 after As2O3 treatment.

Hyperleukocytosis. Hyperleukocytosis, as defined by WBC count superior to 10 × 109/L, developed in 8 of the 11 (72.7%) newly diagnosed patients with WBC counts from 26 to 183 × 109/L (median, 41.5 × 109/L), before, or 5 to 20 days after receiving As2O3 (Fig 1). WBC counts declined with moderate chemotherapy in 2 cases and spontaneously in 4 cases, without occurrence of the related adult respiratory distress syndrome (ARDS) clinical syndromes. Among the others, 2 cases died, hyperleukocytosis may be one of the causes leading to treatment failure in 1 patient.

Toxic effects. The major As2O3-related toxicities, as listed in Table 3, were skin reactions (rash, itching, erythema) (3 of 11), gastrointestinal reactions (vomiting, nausea, and diarrhea) (4 of 11), cardiac dysfunction (1 of 11), similar to those in the relapsed group. However, hepatic damage occurred in 7 of 11 patients with elevation of the serum glutamic pyruvic transaminase (SGPT) ranging from 82 to 918 IU/L (median, 266 IU/L; normal range, 10 to 64 IU/L) and serum glutamic oxaloacetic transaminase (SGOT) 58 to 934 IU/L (median, 114 IU/L; normal range, 10 to 42 IU/L). Among these 7 patients, symptomatic medication was administered and withdrawal of As2O3 was indicated when severe liver dysfunction occurred. Five patients recovered and the other 2 failed. These 2 patients are worth particular attention because of the development of lethal hepatic damage as described below.

Case 2: a 33-year-old woman with previously untreated APL was treated with 10 mg As2O3 daily and continued for 10 days. No previous history of hepatitis was noted and the tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) were negative. The percentage of promyelocytes in BM decreased from 78.5% to 40%. WBC count in peripheral blood increased from 1.1 × 109/L to 9.5 × 109/L, whereas sequential measurement showed that SGPT and SGOT increased from 52 IU/L and 53 IU/L to 633 IU/L and 576 IU/L, respectively. This patient died on day 15 with liver failure: SGPT 918 IU/L, SGOT 934 IU/L, bilirubin 20.6 µmol/L, and alkaline phosphatase 65 IU/L in spite of intensive supportive care. Liver biopsy was not performed because of patient and relatives’ refusal. Renal function test was normal during the treatment. RT-PCR showed positive results of S-type PML-RARα transcript.

Case 8: a 34-year-old woman, with no history of liver dysfunction (SGPT 54 IU/L, SGOT 49 IU/L, bilirubin 4.7 µmol/L, alkaline phosphatase 76 IU/L), received As2O3 as induction therapy. One week later, liver toxicity occurred with SGPT (255 IU/L) and SGOT (305 IU/L) increased significantly, the WBC count and percentage of APL cells in PB reached the highest level (50 × 109/L and 93%, respectively). She died of liver dysfunction.

Table 2. Efficacy of As2O3 Treatment in APL

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Case Numbers</th>
<th>CR (%)</th>
<th>Days to CR (Medium)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newly diagnosed patients</td>
<td>As2O3</td>
<td>7</td>
<td>6 (85.7%)</td>
<td>30 to 36 (35)</td>
</tr>
<tr>
<td></td>
<td>As2O3 + Chemo</td>
<td>4</td>
<td>2 (50.0%)</td>
<td>36 to 36 (36)</td>
</tr>
<tr>
<td>Relapsed patients</td>
<td>As2O3</td>
<td>31</td>
<td>26 (83.9%)</td>
<td>17 to 76 (30)</td>
</tr>
<tr>
<td></td>
<td>As2O3 + Chemo</td>
<td>11</td>
<td>9 (81.8%)</td>
<td>25 to 63 (35)</td>
</tr>
<tr>
<td></td>
<td>As2O3 + ATRA</td>
<td>5</td>
<td>5 (100.0%)</td>
<td>19 to 46 (39)</td>
</tr>
</tbody>
</table>

Table 3. Side Effects of As2O3 in 58 APL Patients

<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Group</th>
<th>Newly Diagnosed Patients</th>
<th>Relapsed Patients</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1 2 3 4 1 2 3 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin reaction</td>
<td></td>
<td>1 2 0 0 8 4* 0 0 NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal reaction</td>
<td></td>
<td>4 0 0 10† 0 0 0 NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac dysfunction</td>
<td></td>
<td>1 0 0 0 8 0 0 0 NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial edema and neuropathy</td>
<td></td>
<td>1 0 0 0 5 0 0 0 NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver dysfunction</td>
<td></td>
<td>2 3 2 0 14 1 0 0 .001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: NS, not significant.
*Including 1 patient received As2O3 + ATRA concurrently.
†Including 2 patients received As2O3 + chemotherapy.
cerebral hemorrhage accompanied with severe liver impairment (SGPT 900 IU/L; SGOT 905 IU/L; bilirubin 14.1 µmol/L, alkaline phosphatase 73 IU/L) and hyperleukocytosis (50×10⁹/L), despite timely withdrawal of As₂O₃ and hepatic supportive treatments. Renal function index was normal during the whole As₂O₃ treatment. She had L-type fusion gene by RT-PCR.

**Disease-free survival.** After CR, five patients received chemotherapy for maintenance whereas three patients received As₂O₃, one (case 9) of the three latter cases being shifted to chemotherapy after two courses of As₂O₃. With a median follow-up of 12 months, all these eight patients are still in CR (range: 8 to 20 months) (Fig 2A).

**Cytogenetics and molecular genetics data.** t(15;17) was found in cases 2 to 9 and 11 when diagnosed, whereas cytogenetic analysis failed in cases 1 and 10 due to lack of metaphase cells. All of the 11 newly diagnosed APL patients were PML-RARα positive by RT-PCR at diagnosis. RT-PCR remained positive in four of five patients when CR was obtained, but became negative after 1 to 3 months of consolidation with chemotherapy in three cases (Fig 3).

## RELAPSED PATIENT GROUP

**Remission induction.** Among the 47 patients treated with As₂O₃, 4 died of cerebral hemorrhage at early days of treatment (one on day 7 and three on day 8) due to low platelet and low fibrinogen (3 cases) or tumor cell infiltration into the central nervous system (1 case). A total of 31 were treated with As₂O₃ alone, 11 with combination of As₂O₃ and moderate chemotherapy, and 5 with As₂O₃ and ATRA. A total of 40 of 47 (85.1%) patients went into CR, whereas the CR rate was 83.9% (26 of 31) when 31 patients receiving As₂O₃ alone were analyzed (Table 2). The overall median time for getting CR was 31 days, with a median dosage, correspondingly, of 310 mg. In the 3 resistant patients (cases 10, 27, and 33), case 10 had 85% APL cells at the onset of relapse and the leukemic cells in BM rose to 71.5% after a transient drop to 38% with initial As₂O₃ treatment, losing response to As₂O₃ or chemotherapy. There was no decrease in blast percentage in case 27 after two courses of As₂O₃ treatment, then the patient was treated with chemotherapy but failed to respond to either. In case 33, the percentage of promyelocytes in the BM increased from 19.5% to 94% after

---

**Fig 2.** (A) Kaplan-Meier product-limit estimate of DFS from the time of CR for newly diagnosed patients. (B) Kaplan-Meier product-limit estimate of DFS and overall survival from the time of CR for relapsed patients. (C) DFS in relapsed APL patients with regard to WBC count at relapse. (D) DFS in relapsed APL patients between arsenic group and combination group.
nearly 2 months of treatment with As$_2$O$_3$ and the patient finally died.

**Hyperleukocytosis.** Hyperleukocytosis developed during As$_2$O$_3$ treatment in 26 of the 47 relapsed patients (55%) with the WBC counts ranging from $11.9 \times 10^9$/L to $167 \times 10^9$/L (median, $38 \times 10^9$/L) after 1 to 43 days (median, 17 days) of treatment. The WBC counts in 11 of 26 patients returned to normal after chemotherapy, including 1 patient who developed ARDS on day 22 of As$_2$O$_3$ treatment when the WBC count was $67.0 \times 10^9$/L, whereas those in the other 14 cases fell to normal spontaneously. One patient presenting hyperleukocytosis died of cerebral hemorrhage with low platelet count and low fibrinogen on day 7.

**Side effects.** As$_2$O$_3$-related toxicities occurred in 12 of 47 with skin reactions, 10 of 47 with gastrointestinal reactions (vomiting, nausea, diarrhea), 15 of 47 with liver dysfunction, 8 of 47 with cardiac dysfunction, and 5 of 47 with facial edema and neuropathy (Table 3). Most of the side effects were modest and responded to symptomatic treatment, further confirming our previous report. There was no difference in frequency or in extent of side effects between patients treated with As$_2$O$_3$ alone and those with combination therapy (As$_2$O$_3$ + chemotherapy or As$_2$O$_3$ + ATRA).

**Disease-free survival.** The follow-up data were available in 33 patients, the other 7 were out of follow-up. As shown in Fig 2B, the estimated DFS rates at 1 and 2 years of the 33 patients followed were 63.6% and 41.6%, respectively, and the median DFS was 17 months. The estimated 1 and 2 year overall survival rates were 72.1% and 50.2%, respectively, whereas the actual median overall survival was 25 months (Fig 2B).

A number of factors with possible influence on the DFS were analyzed. The disease status before As$_2$O$_3$-induced CR was at first relapse in 29, at second relapse in 2, and at third relapse in 2 cases. Of note, 3 of 4 patients treated with As$_2$O$_3$ at advanced stage (the second or third relapse) relapsed again, compared with 14 of 29 treated at the first relapse. More importantly, patients presenting for As$_2$O$_3$ treatment with WBC lower than $10 \times 10^9$/L had DFS significantly better than those with WBC higher than $10 \times 10^9$/L ($P = .038$) (Fig 2C). For postremission therapy after As$_2$O$_3$-induced CR, 4 were treated with chemotherapy alone (from 8 to 17 months), 18 with As$_2$O$_3$ alone (from 7 to 48 months), and 11 with combination therapy (from 11 to 44 months). Disease recurrence developed in 3 of 4 cases treated with chemotherapy alone, 12 of 18 with As$_2$O$_3$ alone, and 2 of 11 with the combination, respectively. Therefore, the duration of CR also tended to be related to postremission treatment protocols, with combination of As$_2$O$_3$ and chemotherapy giving better DFS compared with As$_2$O$_3$ alone ($P = .01$) (Fig 2D).

Table 4 shows the outcomes of the 17 cases that relapsed again after As$_2$O$_3$ treatment. Only one (case 17) patient has regained durable CR for 20 months with chemotherapy and ATRA as the maintenance treatment, whereas others unfortunately died, although a short CR was obtained among 4 cases.

**Cytogenetics and molecular genetics.** Karyotyping was performed successfully in 22 cases at diagnosis of relapse. A total of 19 of 22 had t(15;17) and 3 cases had not. In addition, a complex karyotype, 46,XY,t(5;15)(q14;q22), t(15;17)(q22;q11-21), ins(16;17)(p11;p12;q?), was observed in case 11 when relapse occurred after As$_2$O$_3$-induced CR, which was confirmed by dual-color painting with WCP probes for chromosome 5, 15, 16, and 17.

RT-PCR results were obtained in 29 patients at the time of relapse before As$_2$O$_3$ treatment. Among them, case 10 was PCR negative for PML-RAR$\alpha$ in spite of the fact that fusion gene transcript was positive at first disease presentation. In case 27, both PML-RAR$\alpha$ and AML1-ETO were amplified by RT-PCR though only AML1-ETO was detected by FISH. These two patients showed no response to As$_2$O$_3$ induction as described above. In another nonresponder (case 33), RT-PCR analysis was not obtained due to lack of material.

In the other patients, four cases (cases 4, 5, 25, and 38) had S-type fusion genes, one of whom remained in CR until now, one died, and the other two were lost to follow-up. The remaining 23 cases all showed RT-PCR positivity for L-type.

---

**Fig 3.** RT-PCR and follow-up data of 11 newly diagnosed patients. D, at diagnosis; CR, complete remission; L/S, long/short-type isoform of PML-RAR$\alpha$ transcripts. Arrows indicate treatment protocol, As$_2$O$_3$ or chemotherapy, as postremission therapy.
immediately after As₂O₃-induced hematological CR were available in the remaining 5 cases. RT-PCR data were not available in the remaining 5 cases. RT-PCR data were detected in 14 of 15 cases, indicating that As₂O₃ induction of clinical CR was not associated with molecular CR in the majority of patients (Fig 4). It is worth noting, however, that RT-PCR negative results were obtained in two patients (cases 2 and 3, Fig 4) after long-time maintenance therapy (41 and 37 months, respectively) with As₂O₃ alone.

Presence of t(15;17) in partially differentiated APL cells occurs during As₂O₃ treatment. To evaluate the possible in vivo partial differentiation of APL cells induced by As₂O₃, as suggested by our previous report, fresh APL cells in BM were obtained from five cases during remission induction and analyzed by morphological examination and combination of Wright’s staining and dual-color FISH. These patients all had t(15;17) on chromosome karyotyping and PML-RAR fusion transcripts by RT-PCR at diagnosis of relapse. The percentages of t(15;17) on chromosome karyotyping and PML-RAR fusion gene, which is characteristic of AML-M2, in addition to the t(15;17), was detectable using the FISH method. The in vivo sensitivity to As₂O₃ appears to target PML or PML-RAR onto NB.

DISCUSSION

In the present study, we were able to conduct a multicenter clinical research on 11 previously untreated and 47 relapsed patients. Eight of eleven (72.7%) newly diagnosed patients achieved CR with the median time of 35 days, similar to a previous report in China with a CR rate of 73% in newly diagnosed APL patients. These results are comparable to that obtained by ATRA in newly diagnosed patients. On the other hand, 40 of 47 (85.1%) relapsed APL patients achieved CR. Hence, As₂O₃ is able to induce high CR rate in both newly diagnosed and relapsed APL patients. Among the 51 patients (8 primary and 43 relapsed) who received enough long As₂O₃ remission induction, 3 cases should be considered as nonresponders because they failed to achieve CR even after two courses of the drug. Among these 3 patients, 1 had no available cytogenetic and molecular data, the other 2 cases (10 and 27), although presenting with t(15;17) and PML-RARx at first diagnosis, had altered genotype of leukemic cells at relapse.

Table 4. Response of 17 Patients Relapsed after As₂O₃ to Different Reinduction Protocols

<table>
<thead>
<tr>
<th>Reinduction Protocol</th>
<th>CT</th>
<th>ATRA</th>
<th>As₂O₃</th>
<th>As₂O₃ + ATRA Followed by CT</th>
<th>ATRA Followed by CT</th>
<th>As₂O₃ + ATRA Followed by CT</th>
<th>No Antileukemic Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>Case 24</td>
<td>Case 14</td>
<td>Case 1</td>
<td>Case 12</td>
<td>Case 5</td>
<td>Case 8</td>
<td>Case 43</td>
</tr>
<tr>
<td>Case 35</td>
<td>Case 17</td>
<td>Case 4</td>
<td>Case 16</td>
<td>Case 39</td>
<td>Case 23</td>
<td>Case 11</td>
<td></td>
</tr>
<tr>
<td>Response</td>
<td>2 NR</td>
<td>1 NR</td>
<td>2 NR</td>
<td>2 NR</td>
<td>2 NR</td>
<td>2 CR</td>
<td>2 NR</td>
</tr>
<tr>
<td>Follow-up</td>
<td>2 died</td>
<td>1 died</td>
<td>1 CR</td>
<td>2 died</td>
<td>2 died</td>
<td>1 out of follow-up</td>
<td>2 died</td>
</tr>
</tbody>
</table>

Abbreviation: CT, chemotherapy.

Table 4: Response of 17 Patients Relapsed after As₂O₃ to Different Reinduction Protocols

The table provides a summary of the response of 17 patients who relapsed after treatment with As₂O₃. The data includes the reinduction protocol, the response to treatment, and the combination of treatments used. The table also includes follow-up data and the number of patients with no antileukemic treatment. The table is divided into columns for different combinations of treatments and columns for the response of the patients.
Fig 4. RT-PCR and follow-up data after postremission treatment with As$_2$O$_3$ alone (A), or chemotherapy alone, or chemotherapy/As$_2$O$_3$ combination (B) in 43 relapsed APL patients. D, at diagnosis; CR, complete remission; L/S, long/short-type isoform of PML-RAR$\alpha$ transcripts. * Indicates each time of relapse.

Table 5. Clinical and Laboratory Results in Five Patients After As$_2$O$_3$ Treatment

<table>
<thead>
<tr>
<th>Case No.</th>
<th>BM Promyelocyte (%)</th>
<th>BM Myelocyte (%)</th>
<th>BM Metamyelocyte (%)</th>
<th>Days of Receiving As$_2$O$_3$ Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before As$_2$O$_3$ Treatment</td>
<td>After As$_2$O$_3$ Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>93</td>
<td>1.5</td>
<td>1</td>
<td>28</td>
</tr>
<tr>
<td>22</td>
<td>73</td>
<td>1</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>29</td>
<td>75</td>
<td>8.5</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>35</td>
<td>11</td>
<td>22.5</td>
<td>0</td>
<td>25</td>
</tr>
<tr>
<td>37</td>
<td>64.5</td>
<td>10</td>
<td>3</td>
<td>22</td>
</tr>
</tbody>
</table>
vivo plasma concentration of As$_2$O$_3$ was low (<0.5 to 1 µmol/L) most of the time over the treatment course. One sensible issue on As$_2$O$_3$ treatment is the adverse effects. In this study, when the newly diagnosed and relapsed APL groups were compared, they showed almost similar incidence for hyperleukocytosis, skin reaction, gastrointestinal reaction, and cardiovascular system dysfunction. However, an unexpected finding was that the hepatotoxicity was much higher in newly diagnosed patients than in relapsed ones, because 7 of 11 (63.6%) (2 cases in grade 1, 3 cases in grade 2, and 2 cases in grade 3) newly diagnosed APL patients developed hepatic dysfunction in contrast to 15 of 47 (31.9%) (14 cases in grade 1 and 1 case in grade 2) in relapsed cases ($P < .001$). None of the 7 newly diagnosed patients with liver toxicity presented abnormal liver function tests or HBV or HBC antigens and antibodies before As$_2$O$_3$ treatment. More importantly, among these patients, 2 died with highest SGPT and SGOT levels, 918 IU/L and 934 IU/L (case 2) and 900 IU/L and 905 IU/L (case 8), respectively. Because both patients died on day 15 of As$_2$O$_3$ induction, a period not long enough to achieve CR, it is difficult to evaluate the response with regard to the reduction of leukemia cell population, though hyperleukocytosis appeared in one case, suggesting a possible differentiation-inducing effect of As$_2$O$_3$. Meanwhile, we did not find severe hepatic damage happening in a group of relapsed APL patients treated during the same period with the same batch of As$_2$O$_3$, eliminating the possibility of variation in drug quality.

The significant difference between the two groups could be ascribed to their distinct sensitivity towards the toxic effects of the drug. Recent data suggested that intracellular antioxidant levels may be involved in the defense of cells against arsenite genotoxicity. It was found that the activities of two antioxidant enzymes, catalase and glutathione peroxidase, were 5.4-fold and 5.8-fold lower in xrs-5 cells than those in Chinese hamster ovary (CHO)-k1 cells. The xrs-5 cells are x-ray hypersensitive CHO subclone with higher sensitivity to sodium arsenite inhibition of cell growth and micronuclei induction compared with CHO-k1 cells. Therefore, we postulate that in relapsed patients, long-term treatment with ATRA and/or chemotherapeutic drugs could induce or modify some antioxidant enzymatic system and enhance the antioxidant ability, so they had better tolerance to arsenic than newly diagnosed patients. Another possibility is that patients with higher susceptibility to As$_2$O$_3$-induced damage may belong to a special group with reduced
capacity of drug detoxication and could be already selected out through previous ATRA/chemotherapy. The shortage of materials from our newly diagnosed patient group, unfortunately, did not allow us to perform further study on the enzymes related to the toxicity of As$_2$O$_3$. Because remission induction with ATRA in newly diagnosed APL patients never gives rise to such a severe liver toxicity and the retinoic acid syndrome now can be easily handled, we believe that ATRA should be used as the first-line drug for remission induction, whereas As$_2$O$_3$, until further evaluation of its toxicity, should be incorporated into a multidrug consolidation/maintenance therapy during remission or as a rescue in relapsed patients. Additionally, drugs can be used to relieve the side effects of As$_2$O$_3$ in cases of severe intoxication. As Moore et al reported, 2,3-dimercaptopropionate-sulphonate (DMPS) was able to reduce toxicity of As$_2$O$_3$. Dimercaptosuccinic acid (DMSA) analogues were also put forward to decreasing the tissue content of arsenic in acute As$_2$O$_3$ poisoning in NMRI male mice, suggesting that potentially protective measures are available while using As$_2$O$_3$ to treat the malignancies.

ATRA has been proven to have a highly specific effect on the newly diagnosed APL patients with t(15;17) and PML-RARa expression. Previous studies showed, however, when ATRA was used as the maintenance treatment alone after CR achieved with the same drug, most patients relapsed within 6 months, mainly because of the development of drug resistance. On the contrary, long-time remission was reported in a series of 32 APL patients treated with As$_2$O$_3$ as single therapeutic agent, among whom one fourth had a survival time of more than 10 years, suggesting long-term treatment with As$_2$O$_3$ may induce molecular remission. In the present work, we analyzed this issue by using RT-PCR before and after As$_2$O$_3$-induced CR. It was found that immediately after CR, the leukemic clone persisted in 4 of 5 newly diagnosed patients and 14 of 15 relapsed patients investigated. Therefore, As$_2$O$_3$ induction is not sufficient to induce a molecular remission. Nevertheless, a relatively long DFS (48 and 44 months in cases 2 and 3, respectively) with negative RT-PCR was observed in 2 cases in the relapsed group, indicating that long-term use of As$_2$O$_3$ alone could indeed lead to a molecular remission in some patients. This result suggests that As$_2$O$_3$ may be more potent than ATRA in terms of maintaining molecular/clinical remission and justifies inclusion of As$_2$O$_3$ into multidrug postremission treatment in future clinical trials.

The reason that the effect of ATRA is less durable than As$_2$O$_3$ in treating APL patients could be multiple. As a vitamin-like hormone, ATRA may induce more easily a metabolic resistance than As$_2$O$_3$, an inorganic small compound. Secondly, ATRA mainly induces differentiation of APL cells, whereas As$_2$O$_3$ could induce both apoptosis and partial differentiation of these leukemia cells. Thirdly, although the two drugs share a common target, PML-RARa, As$_2$O$_3$ may exert an effect on a wider spectrum of proteins, whereas the action of ATRA is limited to RA receptors only. For example, As$_2$O$_3$ could modify the phosphorylation of transcription factors such as AP1 or DNA hypomethylation or cause downregulation of bcl-2 protein.

One of the major purposes of this study was to evaluate the outcome of relapsed APL patients after CR achieved with As$_2$O$_3$, to find out possible prognostic factors and what could be the best postremission treatment. Among the 33 relapsed APL patients available for follow-up, the median DFS time was 17 months, whereas relapse occurred in 17 patients. As expected, patients at the second or third relapse before As$_2$O$_3$-induced CR seemed to relapse more frequently (3 of 4) than those at the first relapse before As$_2$O$_3$-induced CR (14 of 29), although more cases should be studied. Next, patients with lower tumor burden as reflected by low WBC counts (below 10 $\times$ 10$^9$/L) showed statistically better DFS than those with higher tumor burden (WBC $> 10 \times 10^9$/L) ($P = .038$). When different treatment protocols were compared, clinical outcome seems to be associated with postremission therapy, since there was only 2 relapses of 11 cases in the combination therapy group, compared with the 12 of 18 with As$_2$O$_3$ treatment ($P = .01$). These results indicate that combination therapy may be the choice of treatment to achieve a longer survival. Furthermore, ATRA could still have a role to play even in patients relapsed after As$_2$O$_3$, because among 17 cases who relapsed again after As$_2$O$_3$-induced CR, only one achieved a DFS for 20 months after reinduction with ATRA and with combined chemotherapy/ATRA as maintenance treatment. It is possible that APL cells in this case restored sensitivity to ATRA, as suggested by a recent study that As$_2$O$_3$ could affect the RA response through changes in proteins involved in the RA pathway. If this is true, then a new strategy to prolong the survival could be designed in which ATRA is incorporated into an As$_2$O$_3$ + chemotherapy + ATRA triple combination after As$_2$O$_3$-induction in relapsed APL patients. An important issue is how to use the three medications. Adverse reactions were similar among relapsed patients who received the combination of As$_2$O$_3$ with ATRA or chemotherapy or As$_2$O$_3$ alone. However, in vitro studies showed that the use of ATRA and As$_2$O$_3$ might interfere with the full effect of each drug. Shao et al found that the ATRA-induced cell differentiation was interfered by As$_2$O$_3$ addition, and the addition of ATRA reduced As$_2$O$_3$-induced cell apoptosis. Hence, sequential use of the two drugs may be better than simultaneous use, as also suggested in SCID mouse-APL model (Chen et al, in preparation).

In conclusion, As$_2$O$_3$ treatment can lead to a high CR rate in both newly diagnosed and relapsed APL patients. However, the severe hepatic adverse effect in some patients does not support As$_2$O$_3$ to be used as a first-line remission-inducing drug. Finally, the As$_2$O$_3$/chemotherapy combination after As$_2$O$_3$-induced CR in relapsed patients yielded better DFS than As$_2$O$_3$ or chemotherapy alone. Long-term use of As$_2$O$_3$ alone is able, at least in part of the patients, to induce a molecular remission, justifying further investigation of its use in a multidrug maintenance therapy after ATRA induced CR and chemotherapy consolidation, in a hope that the DFS in APL could be further improved.

NOTE ADDED IN PROOF

The data listed as unpublished in Discussion were published in J Natl Cancer Inst 91:772, 1999.

ACKNOWLEDGMENT

The authors thank all members of Shanghai Institute of Hematology for their support and encouragement and thank Prof Anne Hagemeijer for kindly giving us the P1 164 and C664 clones that were used as probes for FISH in the detection of AML1-ETO. We also thank Prof...
REFERENCES


Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients

Chao Niu, Hua Yan, Ting Yu, Hui-Ping Sun, Jian-Xiang Liu, Xiu-Song Li, Wen Wu, Fen-Qin Zhang, Yu Chen, Li Zhou, Jun-Min Li, Xiao-Ying Zeng, Ren-Rong Ou Yang, Mi-Man Yuan, Mei-Yu Ren, Feng-Ying Gu, Qi Cao, Bo-Wei Gu, Xin-Ying Su, Guo-Qiang Chen, Shu-Min Xiong, Ting-dong Zhang, Samuel Waxman, Zhen-Yi Wang, Zhu Chen, Jiong Hu, Zhi-Xiang Shen and Sai-Juan Chen